Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 304-314

  Zhao, Xiaochen ^a   Venkata, Swarajya Lakshmi Vattem ^b   Moaddel, Ruin ^b   Luckenbaugh, Dave A ^c   Brutsche, Nancy E ^c   Ibrahim, Lobna ^c   Zarate, Carlos A ^c   Mager, Donald E ^a   Wainer, Irving W ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b National Institute on Aging Intramural Research Program   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

(2S, 6S; 2R, 6R) hydroxynorketamine; (R, S) dehydronorketamine; (R, S) norketamine; Bipolar depression; Stereoselectivity

Indexed keywords

DEHYDRONORKETAMINE; DRUG METABOLITE; HYDROXYKETAMINE; HYDROXYNORKETAMINE; KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ANALYTIC METHOD; ARTICLE; BIPOLAR DEPRESSION; CHEMICAL STRUCTURE; CHROMATOGRAPHY; CLINICAL ARTICLE; COMPARTMENT MODEL; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84863734573     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04198.x     Document Type: Article

References (29)

1. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87: 1186-93.
2. Domino EF. Taming the ketamine tiger. Anesthesiology 2010; 113: 678-86.
3. Schwarztman RJ, Alexander GM, Grothusen JR. The use of ketamine in complex regional pain syndrome: possible mechanisms. Expert Rev Neurother 2011; 11: 719-34.
4. Sabia M, Hirsh RA, Torjman MC, Wainer IW, Cooper N, Domsky R, Goldberg ME. Advances in translational neuropathic pain research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome. Curr Pain Headache Rep 2011; 15: 207-14.
5. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK, Beach ML. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology 2010; 113: 639-46.
6. Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med 2010; 28: 820-7.
7. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-asparate antagonist in treatment resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64.
8. Diazgranados N, Ibraham L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji KM, Zarate CA. A randomized add-on trial of an N-methyl-D-asparate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-801.
9. Diazgranados N, Ibraham LA, Brutsche NE, Ameli RA, Henter ID, Luckenbaigh DA, Machado-Vieira R, Zarate CA. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-asparate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-11.
10. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009a; 2009: 304-11.
11. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofson ES. Ketamine effect on experimental pain and cardiac output. Anesthesiology 2009; 111: 892-903.
12. Dahan A, Olofsen E, Sigtermans M, Noppers I, Niesters M, Aarts L. Population pharmacokinetic-pharamcodynamic modeling of ketamine-induced pain relief of chronic pain. Eur. J. Pain 2010; 15: 258-67.
13. Leung LY, Baillie TA. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29: 2396-9.
14. Herd DW, Anderson BJ, Holford NHG. Modeling the norketamine metabolite in children and the implications for analgesia. Pediatr Anesth 2007; 17: 831-40.
15. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behavior 2008; 90: 676-85.
16. Trevor AJ, Woolf TF, Baillie TA, Adams JD, Castagnoli N. Stereoselective Metabolism of Ketamine Enantiomers, Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications, eds Kamenka JM, Domino EF, Geneste P. Ann Arbor, MI: NPP Books, 1983; 279-89.
17. Portmann S, Kwan HT, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary electrophoresis for the identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatog A 2010; 1217: 7942-8.
18. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist 1975; 24: 260-3.
19. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993; 70: 666-71.
20. Ihmsen H, Geisslinger G, Schuttler J. Stereoselective pharmacokinetics of ketamine: R-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001; 70: 431-8.
21. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Bopharm Drug Disp 2003; 24: 37-43.
22. Goldberg ME, Torjman MC, Schwartzman RJ, Mager DE, Wainer IW. Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality 2011; 23: 138-43.
23. Bolze S, Boulieu R. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high-purity reversed-phase sorbent. Clin Chem 1998; 44: 560-4.
24. Williams ML, Mager DE, Parenteau H, Gudi G, Tracy T, Mulheran M, Wainer IW. Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos 2004; 32: 786-93.
25. Theurillat R, Knobloch M, Schmitz A, Lassahn P-G, Mevissen M, Thormann W. Enantioselective analysis of ketamine and its metabolites in equine plasma and urine by CE with multiple isomer sulfated β-CD. Electrophoresis 2007; 28: 2748-57.
26. Larenza MP, Peterbauer C, Landoni MF, Levionnois OL, Schatzmann U, Spadavecchia C, Thormann W. Stereoselective pharmacokinetics of ketamine and norketamine after constant rate infusion of a subanesthetic dose of racemic ketamine or S-ketamine in Shetland ponies. Am J Vet Res 2009; 70: 831-9.
27. Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT. Use of human microsomes and deuterated substrates; an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 2009; 37: 1769-78.
28. Moaddel R, Venkata SLV, Tanga MJ, Bupp JE, Green CE, LaIyer L, Furimsky A, Goldberg ME, Torjman MC, Wainer IW. A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta 2010; 82: 1892-904.
29. White M, de Graaff P, Renshof B, van Kan E, Dzoljic M. Pharmacokinetics of S(+) ketamine derived from target controlled infusion. Br J Anaesth 2006; 96: 330-4.